Whitehawk Therapeutics: 'Hold' On Name Change, Next Generation PTK7 ADC Targeting (WHWK)
· seekingalpha.com
Whitehawk Therapeutics pivots to focus on three next-generation antibody-drug conjugates after selling FYARRO. See why WHWK stock is downgraded to hold.
This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you ...